Video

WCLC Updates in Immunotherapy for NSCLC

Author(s):

Stephen Liu, MD, Georgetown Lombardi Comprehensive Cancer CenterSarah Goldberg, MD, MPH, Yale School of Medicine

Key opinion leaders discuss recent trial data on the clinical efficacy of immunotherapy for the treatment of non–small cell lung cancer (NSCLC).

Data from the following clinical trials are discussed:

  • OA01.06 - Randomized Phase 2 Study of Nivolumab (N) Versus Nivolumab and Ipilimumab (NI) Combination in EGFR-Mutant NSCLC
  • PS01.09 - Pembrolizumab Plus Ipilimumab vs Pembrolizumab Plus Placebo as 1L Therapy for Metastatic NSCLC of PD-L1 TPS ≥50%: KEYNOTE-598
  • OA01.03- Clinical Benefits of First-line (1L) Cemiplimab Monotherapy by PD-L1 Expression Levels in Patients With Advanced NSCLC
Related Videos
Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, experts on lung cancer
Five-year outcomes with first-line (1L) nivolumab + ipilimumab + chemotherapy (N + I + C) vs C in patients (pts) with metastatic NSCLC (mNSCLC) in CheckMate 9LA
Benjamin Levy, MD
Lorlatinib vs Crizotinib in Treatment-Naive Patients With Advanced ALK+ Non-Small Cell Lung Cancer: 5-Year Progression-Free Survival and Safety From the CROWN Study
Chinmay Jani, MD, clinical fellow, Hematology & Oncology, Sylvester Comprehensive Cancer Center at the University of Miami/Jackson Memorial Hospital
Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, experts on lung cancer
Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, experts on lung cancer
David R. Spigel, MD, chief scientific officer, Sarah Cannon Research Institute
Video 6 - "Reflex Testing for Patients with Suspected Lung Cancer"
Video 5 "Biomarker Testing in Early-Stage NSCLC"
Related Content
Ying Cheng, MD
June 18th 2024

China’s NMPA Gives Go Ahead to Toripalimab Plus Chemotherapy in First-Line ES-SCLC

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

FDA
June 17th 2024

FDA Approval Sought for Subcutaneous Amivantamab in EGFR+ NSCLC

Hari B. Keshava, MD
October 23rd 2023

Keshava Emphasizes the Importance of Lung Nodule Programs for Early Lung Cancer Detection

Luis G. Paz-Ares, MD, PhD, chair, Medical Oncology Department, Hospital Universitario 12 de Octubre; associate professor, Universidad Complutense de Madrid
June 11th 2024

Lurbinectedin Plus Irinotecan Is Safe, Prolongs Responses in High-Risk, Pretreated SCLC

Fabrice Barlesi, MD, PhD
June 10th 2024

Adjuvant Alectinib Approved in Europe for ALK+ Early-Stage NSCLC